Synopsis: Motilal Oswal initiated coverage on Rubicon Research with a ‘Buy’ rating and Rs. 930 target, which is 27% upside from current levels citing strong R&D capabilities, 29% revenue and 43% PAT CAGR outlook, over 30% RoE, and potential 50% upside.

This company is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations is now in the focus after Motilal Oswal gave a ‘BUY’ Target.

With market capitalization of Rs. 12,107 cr, the shares of Rubicon Research Ltd are currently trading at Rs. 730 per share, from its previous close of Rs.744.05 per share. This company was listed on October 16th 2025, listed at a price of Rs. 620.00, which is 27.84% higher than the allotment price.

MOSL Target & Rationale on Rubicon Research

See Full Page